Hold UNH with puts through Oct 13 binary catalyst; 200 SMA at $352 is structural floor; 50 SMA reclaim at $391 needed for bullish re-engagement
Maintain UNH at neutral weight with stops at $360 daily close and $349.61 weekly close. Pre-binary-catalyst Underweights in this exact pattern have bled alpha twice running (10-01 and 10-02), and the calibrated response is Hold-with-puts rather than active trims. The Polymarket 86% beat pricing creates negative expected value on a simple beat—only magnitude beats or raised guidance move the stock. The $352 200 SMA backed by $24B FCF, A-rated balance sheet, and 0.62 defensive beta is a structural floor that nine prior cycles have defended. Sell forfeits the 2.54% dividend capture and re-rating optionality. The binding 10-02 reflection explicitly overrides any "trim toward 3-4%" suggestion for outsized accounts.
| Position | Action |
|---|---|
| No active trim and no fresh capital deployment ahead of Oct 13 Q3 earnings | Maintain neutral weight within healthcare allocation |
| Pre-binary-catalyst Underweights in this pattern (already bled alpha twice) | Default to Hold-with-puts rather than active trims |
| Asymmetric entry levels ($391 50 SMA reclaim with volume, or $352 200 SMA retest) not present at current $378.58 | No new position entry; hold existing |
UNH is a structurally superior, vertically integrated healthcare platform trading at a compelling forward P/E of 16.74x with 7.1% FCF yield and multiple near-term bullish catalysts aligned.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | $352.81 | bullish |
| close_50_sma | $391.23 | bearish |
| close_10_ema | $374.08 | bullish |
| rsi | 48.08 | neutral |
| macd | -5.54 | neutral |
| macds | -6.15 | neutral |
| macdh | +0.61 | bullish |
| boll | $377.37 | neutral |
| boll_ub | $392.56 | neutral |
| boll_lb | $362.19 | neutral |
| atr | 8.82 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: 200 SMA retest at $352
Then: Potential add on flush to this level (acknowledged as catching a falling knife with 32% drawdown risk to 2025 lows)
↩ rebuts: “Bear 'hold until $391 reclaim' recommendation chases rather than buys value”
EV: +13 to $391 (primary), +17 to $408 (secondary) · concedes: The 52-week range of 80% does reflect a wide historical band, though this was event-driven and has since 50% mean-reverted; TTM P/E of 24.3x is technically elevated on backward-looking basis; Beta of 0.62 may be understated given the 80% 52-week range
UNH at $378.58 has negative expected value for fresh capital given the three failed 50 SMA reclaim attempts, an 86%-priced-in earnings beat creating asymmetric risk, a PEG of 1.01 offering no margin of safety, and rising regulatory tail risk (DOJ antitrust, PBM reform, MA audits) against a stock with an 80% trading range spread reflecting binary event exposure.
· concedes: UNH is a high-quality compounder with a real franchise; Vertical integration is a real competitive moat against competitors; Dividend is real; Over 5-10 years, UNH is probably a winner; FCF growth from $6.30B to $10.25B YoY (+63%) is a real number; 200 SMA holding at $352.81 is a real support level
→ vs conservative: Waiting for 'confirmation' at 352 retest to buy means chasing at 410 if it reclaims 391, or missing the entry entirely—'the whole point of asymmetric entries is that you scale into fear, not away from it'
→ vs neutral: Using 86% Polymarket beat probability as reason to sit on hands is 'genuinely one of the most counterproductive applications of crowd-sourced data'—high beat probability means low bar and enormous asymmetry from magnitude beat plus raised guidance
→ vs neutral: Calling this a 'mid-cycle recovery' misses that this is a once-in-a-cycle opportunity being thrown at us due to tape fear over binary risk around October 13 print
→ vs conservative: Using Q4 2025 disaster as tail risk after four quarters of margin normalization, capital return, and balance sheet repair is 'a permanent bear case in disguise'
→ vs conservative: 50 SMA failing three times is not distribution but a 'coil' with three higher lows forming under a falling short-term moving average—'that's not analysis, that's a stopped-out pattern masquerading as prudence'
Support: 362.19 · 365.2 · 352.81 | Resistance: 391.23 · 392.56
UNH exhibits a three-tier regime: long-term bullish (price +7.3% above rising 200 SMA), medium-term bearish (price -3.2% below falling 50 SMA), and short-term cautiously constructive (10 EMA curling up, RSI rebounding from 33.18 to 48.08, MACD histogram positive at +0.61). The Bollinger middle ($377.37) has been reclaimed with lower band ($362.19) successfully defended, but the falling 50 SMA at $391.23 remains the critical resistance — until reclaimed, this remains a counter-trend bounce within a corrective phase rather than confirmed trend resumption. ATR compression to 8.82 (from peak 12.72) indicates a volatility expansion event is imminent. Recommendation: HOLD / Wait for confirmation above $391.
Market Cap
$339.81 B
P/E (TTM)
24.35x
Forward P/E
16.74x
PEG Ratio
1.01
P/B
3.48x
Dividend Yield
2.5%
Beta
0.615
Revenue (TTM)
$450.5 B
EBITDA
$26.68 B
Net Income (TTM)
$14.12 B
EPS (TTM)
$15.55
Forward EPS
$22.61
Gross Margin
19.7%
Operating Margin
7.13%
Net Profit Margin
3.14%
ROE
14.15%
ROA
4.87%
Total Assets
$309.7 B
Total Equity
$105.9 B
Total Debt
$73.3 B
Net Debt
$44.7 B
Cash & Equivalents
$31.5 B
Goodwill
$110.6 B
Current Ratio
0.78
FCF (TTM)
$24.27 B
Annualized Dividends
~$8.2 B
CapEx (quarterly avg)
~$0.86 B
52-Week High
$461.62
52-Week Low
$255.97
50-Day MA
$393.74
200-Day MA
$356.35
Strengths
Concerns
UNH is a high-quality, defensive compounder in the middle of a clear earnings and cash-flow recovery from a 2025 trough. The valuation (forward P/E 16.7x) and FCF inflection ($24.27B TTM) create a compelling medium- to long-term setup, but short-term price action is weak with the stock trading below its 50-day moving average. The dual-platform model (UnitedHealthcare + Optum) provides structural vertical integration advantages, while ongoing deleveraging and resumed buybacks signal management confidence. Key risks include goodwill impairment exposure, regulatory headwinds, and the historical trough metrics from Q4-2025 that continue to distort TTM averages.
Macro: Fed expected to hold rates through 2026 (96% odds per prediction market); US recession odds at 8% by end-2026 (down 1pp WoW); weak September jobs report reducing hike probability and pushing gold higher; Nasdaq hitting fresh highs while Dow and small caps lag; healthcare sector defensively bid into earnings. FRED macro indicators unavailable; analysis relies on prediction market signals and news flow.